SGLT2 inhibitors consist of different mechanisms of glucose control effect with reduced insulin resistance and sustained long-term glycemic control; insulin-independent action ensures longer control, systolic blood pressure, BMI, albuminuria, visceral fat, uric acid, plasma volume, arterial stiffness, inflammation, oxidative stress, sympathetic nervous system, and major adverse cardiac events [33,37,38,39,40]. The gene discussed is INS; the disease is Insulin resistance.